The F8 formulation is 8 times more concentrated than Egrifta and 2 times more concentrated than the current F4 formulation, Egrifta SV.

The study by Sari Reisner and colleagues1 in The Lancet HIV on gender-affirming hormone therapy and its effect on HIV ...

Two Colorado medical researchers trying to stop HIV and AIDS got letters this month saying their federal funding has been ...

If the past four decades have taught us anything about HIV, it's to adjust our expectations—despite enormous progress in ...

Gender-affirming hormone therapy (GAHT) is associated with significantly improved HIV outcomes for transgender, nonbinary, ...

Researchers studied the relationship between age and the risk for skin cancer and oncovirus infections among patients with HIV.

A phase 2 trial will evaluate leronlimab’s safety and efficacy for the treatment of patients with microsatellite stable ...

People with AIDS also have HIV, as HIV is the first stage of AIDS. Learn about the differences, how the conditions overlap, ...

The global HIV antivirals market is experiencing substantial growth, fueled by rising global awareness, advancements in pharmaceutical research, and the increasing adoption of innovative treatment ...

In our 35th year we’re asking people to donate £35 – that’s just £1 for every year we’ve been providing life-changing information. Any donation you make helps us continue our work towards a world ...

Research programs that would help make the HIV response more effective and affordable have been slashed. This will make it more difficult for officials as they look to guide the response forward ...

HIV symptoms vary by the stage of infection, known as acute HIV infection (Stage 1), chronic HIV infection (Stage 2), and AIDS (Stage 3). During primary infection, the symptoms are caused by the virus ...